[ad_1]
Corona virus vaccine results were boosted by Pfizer Pfizer Inc IS BioNTech SE, Germany Optimism that the world will soon have a possible way out of the epidemic, but experts have warned that the vaccine still faces many obstacles that need to be removed..
According to a report by the Bloomberg agency, questions related to the production, distribution and, most importantly, the performance and capacity of the vaccine itself have yet to be answered, although the numbers look very promising and, according to vaccine specialists, an experiment is started. Pfizer Less than four months ago, how long the vaccine will protect and how much benefit from the vaccine is almost unknown at the moment.
“The main question remains focused on time, will time tell us that protection remains beneficial to a larger population?” Said Michael Kensch, drug development expert and associate assistant consultant at Washington University in St. Louis.“
Where two companies were produced Pfizer IS BioNTech Positive results after just over 11 months from onset Crown In China, an initial analysis of data from the experience of over 40,000 volunteers indicated that the vaccine was more than 90% effective in preventing the disease.
The potential success of the first vaccine in a large, late-stage study has given hope that other studies, such as the one developed by the company, will also be successful. Moderna Inc IS AstraZeneca Plc With the University of Oxford, however, infectious disease researchers have warned against excessive enthusiasm for the limited data disclosed by Pfizer..
Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota, said the companies’ statement “never tells us what they actually accomplished” is far too early to define what this new vaccine research shows us. .. “
“The leading figure for symptomatic case reduction by 90% tells us very little about the type of cases being prevented. Details on how the vaccine works well in the elderly and other vulnerable groups who need protection most are yet to come.” , he added..
Ujur Shaheen, CEO, said BioNTech About half of the study participants are elderly and it is possible to expect from the current results that efficacy among the elderly should be greater than 80% and said that further analyzes are needed to confirm..
He said it’s still difficult to aggregate the five serious cases that the U.S. Food and Drug Administration has said it wants to see in vaccine trials, because the rate of serious infections has declined as the outbreak progresses and treatment improves..
Experts have indicated whether an emergency permit has been granted for the Pfizer vaccine FDA A second panel of external experts will invite the Centers for Disease Control and Prevention to intervene promptly to determine who should receive the vaccine first, and only in this case the distribution.
.
[ad_2]
Source link
